Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024

TBPH 10.24.2024

Full Press ReleaseSEC FilingsOur TBPH Tweets

About Gravity Analytica

Recent News

  • 12.17.2024 - Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
  • 12.03.2024 - 7th Annual Evercore HealthCONx Conference
  • 11.20.2024 - Theravance Biopharma to Participate in an Upcoming Investor Conference

Recent Filings

  • 01.21.2025 - 144 Report of proposed sale of securities
  • 11.22.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors

DUBLIN,Oct. 24, 2024/PRNewswire/ --Theravance Biopharma, Inc.(NASDAQ: TBPH) will report its third quarter 2024 financial results and provide a business update after market close onTuesday, November 12, 2024. An accompanying conference call and simultaneous webcast will be hosted at5:00 pm EST(2:00 pm PST/10:00 pm GMT) that day.

Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)

Conference Call Information

To participate in the live call by telephone, please pre-registerhere. Those interested in listening to the conference call live via the internet may do so by visitingTheravance Biopharma'swebsite atwww.theravance.com, under the Investors section, Events and Presentations.

A replay of the webcast will be available onTheravance Biopharma'swebsite for 30 days throughDecember 12, 2024.

AboutTheravance Biopharma

Theravance Biopharma, Inc.'sfocus is to deliverMedicines that Make a Difference®in people's lives. In pursuit of its purpose,Theravance Biopharmaleverages decades of expertise, which has led to the development of FDA-approved YUPELRI®(revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visitwww.theravance.com.

THERAVANCE BIOPHARMA®, THERAVANCE®and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in theU.S.and certain other countries).YUPELRI®is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:investor.relations@theravance.com650-808-4045

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-third-quarter-2024-financial-results-on-november-12-2024-302285433.html

SOURCETheravance Biopharma, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com